XPH’s 29% Run Looks Tempting, But The 5y Chart Is A Warning

Quick Read SPDR S&P Pharmaceuticals ETF (XPH) returned 29.44% over one year versus the S&P 500’s 12%. XPH gained only 10.49% over five years while the broader market returned 74.77%. XPH’s equal weighting amplifies impact of clinical trial failures at smaller portfolio companies. A recent study identified one single habit that doubled Americans’ retirement savings and moved retirement from dream, to reality. Read more here. SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH) exists to solve a specific p ...